SABIRA-250

Abirateraone Acetate 250mg tablets are used to treat cancer of the prostate gland in men. This medicine works by slowing down the growth of cancer cells in the body by reducing the production of male hormones. It should be used with other drugs under the advice of an oncologist.
SABIRA 250 is available in a pack size of 120 tablets. It is suitable for long-term treatment plans. The drug is produced under the strictest quality standards.

 

How Does Abirateraone Acetate 250mg tabletsWorks?

Prostate cancer needs male hormones like testosterone to develop and progress. Abirateraone acetate tablets interrupt the body's natural production of these hormones. When the hormones are reduced, the growth of cancer cells tends to slow down. This has shown positive effects on the control of cancer and the results of the treatment. 

Medical Benefits

• Helps manage advanced prostate cancer 
• Slows down the growth of cancer cells
•  Reduces male hormone production
•  Supports long-term cancer treatment
• Used under medical supervision

 
This medicine should always be taken under the guidance of a cancer specialist.
 
Directions for Use

•  Take the tablet exactly as prescribed by the doctor.
•  Swallow whole with water.
•  Usually taken on an empty stomach.
•  Do not crush or chew the tablet.
•  Follow the complete treatment schedule.
•  Do not stop the medicine without consulting your doctor.

 
Storage Instructions

•  Store in a cool and dry place.
• Keep away from direct sunlight.
• Protect from moisture.
• Keep out of reach of children.

 
Precautions

•  Inform your doctor about liver problems.
•  Regular blood tests may be required during treatment.
•  Not recommended for women or children.
•  Avoid missing doses.
•  Report any unusual symptoms to your doctor immediately.

 
Possible Side Effects

•  Some patients may experience:
•  Weakness or tiredness
•  High blood pressure
•  Joint swelling
•  Changes in liver function
•  Low potassium levels

Most side effects can be managed with medical supervision. Always follow your doctor’s advice.

 

Abirateraone Acetate 250 mg Tablets  Supplier, PCD Franchise & Third Party Manufacturing Opportunities

 
There is growing demand for oncology medicines in India and other markets. Companies looking to expand can connect with an Abirateraone Acetate 250 mg Tablets Pharma Franchise Company for distribution opportunities. Business partners can also explore options under Abirateraone Acetate 250 mg Tablet PCD Pharma Franchise models for regional marketing rights.
 
Many pharma groups collaborate with Abirateraone Acetate 250 mg Tablets PCD Pharma Franchise Company or an Abirateraone Acetate 250 mg Tablets PCD Pharma Company to strengthen their oncology product range.
 
For other bulk production requirements, Abirateraone Acetate 250 mg Tablets Third Party Manufacturing Company or reliable Abirateraone Acetate 250 mg Tablet Third Party Contract Manufacturers may be consulted. Reputed third parties facilitating 3rd party manufacturing of Abirateraone Acetate 250 mg Tablets are prerequisites of quality production with appropriate certification.

The distributors or hospitals may also obtain the required products from reliable Abirateraone Acetate 250 mg Tablet Suppliers for the on-time and secure delivery of products. SABIRA-250 is manufactured with quality checks to maintain higher standards of oncology treatment.


Faq's
 
Q1. What is Abirateraone Acetate 250 mg used for?
It is used in the treatment of prostate cancer in men.
 
Q2. How should it be taken?
It is usually taken on empty stomach as prescribed by a doctor.
 
Q3. Is medical monitoring required?
Yes, regular check-ups and blood tests are important during treatment.
 
Q4. Can patients stop the medicine suddenly?
No, treatment should only be stopped after consulting the doctor.

 
Conclusion
 
Abirateraone Acetate 250 mg Tablets has a significant role to play in the treatment of prostate cancer. If used properly with the help of medical guidance, the condition can be managed properly. SABIRA-250 is produced carefully to meet the requirements of the quality standards and the needs of oncology treatment.